Intravenous Infusions (XGHA:IIL) OCF Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Intravenous Infusions OCF Margin %?

Intravenous Infusions XGHA:IIL +8.86% OCF Margin % is 0.00% as of . 20. Among 964 Drug Manufacturers companies, Intravenous Infusions ranks worse than 103734.34% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Intravenous Infusions's Cash Flow from Operations for the six months ended in . 20 was GHS0.00 Mil. Intravenous Infusions's Revenue for the six months ended in . 20 was GHS0.00 Mil. Therefore, Intravenous Infusions's OCF Margin % for the quarter that ended in . 20 was 0.00%.

As of today, Intravenous Infusions's current OCF Yield % is 0.00%.

The historical rank and industry rank for Intravenous Infusions's OCF Margin % or its related term are showing as below:


XGHA:IIL's OCF Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 10.06
* Ranked among companies with meaningful OCF Margin % only.

Intravenous Infusions OCF Margin % Related Terms

Intravenous Infusions OCF Margin % Historical Data

* Premium members only.

The historical data trend for Intravenous Infusions's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intravenous Infusions OCF Margin % Chart

Intravenous Infusions Annual Data
Trend
OCF Margin %

Intravenous Infusions Semi-Annual Data
OCF Margin %

Intravenous Infusions OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Intravenous Infusions's OCF Margin for the fiscal year that ended in . 20 is calculated as

OCF Margin=Cash Flow from Operations (A: . 20 )/Revenue (A: . 20 )
=/
= %

Intravenous Infusions's OCF Margin for the quarter that ended in . 20 is calculated as

OCF Margin=Cash Flow from Operations (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Intravenous Infusions (XGHA:IIL) has a OCF Margin % of 0.00% as of . 20. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 964 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' OCF Margin % too high?
Intravenous Infusions' current OCF Margin % is 0.00%. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 964 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' OCF Margin % compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 964 companies for OCF Margin %. This places Intravenous Infusions in the lower half of its industry. The industry median OCF Margin % is 10.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.06, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current OCF Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Intravenous Infusions Business Description

Address Plot 4/7 Blk L, P.O Box KF 63, Effiduase-Koforidua, GHA
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.